Navigation Links
Discovery Labs Reports First Quarter 2012 Financial Results
Date:5/3/2012

hich there frequently are few or no approved therapies.  For more information, please visit our website at www.Discoverylabs.com.

About SURFAXIN
SURFAXIN (lucinactant intratracheal suspension) is indicated for the prevention of respiratory distress syndrome (RDS) in premature infants at high risk for RDS.  A single randomized, active-controlled, multi-dose study involving 1,294 premature infants demonstrated the safety and efficacy of SURFAXIN. Within 30 minutes of birth, infants in the study received SURFAXIN, Exosurf (colfosceril palmitate) or Survanta® (beractant).  Surfaxin and Exosurf served as the primary comparison for this study; Survanta served as another comparison.  Surfaxin demonstrated significant improvement in both RDS at 24 hours after birth and RDS-related mortality through two weeks, when compared with Exosurf.

SURFAXIN is intended for intratracheal use only.  The administration of exogenous surfactants, including SURFAXIN, can rapidly affect oxygenation and lung compliance.  SURFAXIN should be administered only by clinicians trained and experienced with intubation, ventilator management, and general care of premature infants in a highly supervised clinical setting. Infants receiving SURFAXIN should receive frequent clinical assessments so that oxygen and ventilatory support can be modified to respond to changes in respiratory status.  Most common adverse reactions associated with the use of SURFAXIN are endotracheal tube reflux, pallor, endotracheal tube obstruction, and need for dose interruption.  During SURFAXIN administration, if bradycardia, oxygen desaturation, endotracheal tube reflux, or airway obstruction occurs, administration should be interrupted the infant's clinical condition assessed and stabilized. SURFAXIN is not indicated for use in acute respiratory distress syndrome (ARDS).  For more information about SURFAXIN,
'/>"/>

SOURCE Discovery Laboratories, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Genomic Health and OncoMed Announce Strategic Alliance for Biomarker Research and Discovery Using Next Generation Sequencing
2. AnaptysBio Announces Antibody Discovery Partnership With Gilead Sciences
3. UWM discovery advances graphene-based electronics
4. Mars, Incorporated Answers Question: How Does Feeding People and Pets Nurture Science and Discovery? At TEDMED 2012
5. AlphaBio Centrix, LLC Announces a New Discovery for Programming Energetic Patches
6. Discovery in Nature elucidates immune cells in skin and supports novel vaccine approach
7. Thomson Reuters Cortellis Drives Drug Discovery and Development With Powerful New Web Services
8. Discovery opens door to low-cost negative refraction, new products and industries
9. AnaptysBio Announces New Strategic Antibody Discovery
10. Thomson Reuters Research Forecasts the Onset of the Targeted Drug Discovery Era
11. Discovery of a dark state could mean a brighter future for solar energy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: ... and Chief Executive Officer, will present live at ... May 7, 2015     TIME:  11:30 am ET/8:30 am ... the red "register/ watch presentations" button ... where investors are invited to ask the company ...
(Date:5/5/2015)... Washington, and WASHINGTON, D.C., USA (PRWEB) May 05, 2015 ... on U.S. export regulations covering a wide range of ... industry say are hampering global competitiveness of U.S. industry. ... host a webinar on 12 May on ... XII, which governs the commodities covered by International Traffic ...
(Date:5/5/2015)... Research and Markets ( http://www.researchandmarkets.com/research/x5gjj3/clinical ... "Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services ... Global Version" report to their offering. ... of molecular diagnostics and pharmacogenics hold the promise ... that is moving out of the national and ...
(Date:5/5/2015)... , May 5, 2015 CytomX, a ... cancer, today announced that Sean McCarthy , D. ... Suisse Antibody Day in New York ... Dr. McCarthy will present an overview of CytomX,s Probody ... drug conjugate programs. About CytomX Therapeutics ...
Breaking Biology Technology:ImmunoCellular Therapeutics to Webcast Live at VirtualInvestorConferences.com on May 7 2Comments needed now from photonics industry on revisions of U.S. export rules 2Comments needed now from photonics industry on revisions of U.S. export rules 3Comments needed now from photonics industry on revisions of U.S. export rules 4Global Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services Market Trends and Forecast 2015 to 2019 2
... ,, HARBIN, China , ... One Medical,Inc. ("China Sky One Medical" or "the ... pharmaceutical company producing over-the-counter drugs in, the People,s ... its Tian Long,Pharmaceutical Company ("Tian Long") subsidiary successfully ...
... May 27 /PRNewswire-Asia-FirstCall/ -- Concord Medical Services,Holdings Limited ("Concord ... the largest network of radiotherapy and diagnostic imaging centers,in China ... March 31, 2010 (1). , , First ... in the first quarter of 2010 were RMB76.2 million, ...
... 27, 2010 , , , ... - New Trial Results on ExoSeal(TM) Vascular Closure Device Support its,Clinical Safety* and Efficacy ... Cordis Corporation, a worldwide ... Vascular Closure Device. ExoSeal(TM) incorporates a number of new,advances in technology and simplicity of ...
Cached Biology Technology:China Sky One Medical Receives GMP Re-Certification 2China Sky One Medical Receives GMP Re-Certification 3Concord Medical Announces First Quarter 2010 Financial Results 2Concord Medical Announces First Quarter 2010 Financial Results 3Concord Medical Announces First Quarter 2010 Financial Results 4Concord Medical Announces First Quarter 2010 Financial Results 5Concord Medical Announces First Quarter 2010 Financial Results 6Concord Medical Announces First Quarter 2010 Financial Results 7Concord Medical Announces First Quarter 2010 Financial Results 8Concord Medical Announces First Quarter 2010 Financial Results 9Concord Medical Announces First Quarter 2010 Financial Results 10Concord Medical Announces First Quarter 2010 Financial Results 11Concord Medical Announces First Quarter 2010 Financial Results 12Concord Medical Announces First Quarter 2010 Financial Results 13Concord Medical Announces First Quarter 2010 Financial Results 14Concord Medical Announces First Quarter 2010 Financial Results 15CORDIS Launches ExoSeal(TM) Vascular Closure Device 2CORDIS Launches ExoSeal(TM) Vascular Closure Device 3CORDIS Launches ExoSeal(TM) Vascular Closure Device 4
(Date:4/14/2015)... 2015  HYPR Corp. today announced it has ... Alliance tm , an industry consortium transforming online ... share technology and collaborate to deliver open specifications ... secure and private, and easier to use. ... protects sensitive user information and eliminates the dependency ...
(Date:4/10/2015)... , April 10, 2015 ... addition of the "Security Competitive Profiles - NEC" ... http://photos.prnewswire.com/prnh/20130307/600769) , NEC will continue to supply ... to the market, with a company focus on the ... anticipated. Winning opportunities in the ...
(Date:4/2/2015)... April 2, 2015 In ... by far outperforms the strongest competitors, showing outstanding ... accuracy, the system is capable of a throughput ... proves up to be ten times faster than ... runner-up performance.      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3NEC Security Competitive Profile 2015 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3
... This release is available in French . ... of Medicine and the CHUQ Research Center have proven that ... Duchenne muscular dystrophy. The team, led by Professor Jacques P. ... published today in the online version of the scientific journal ...
... Program will feature new study results from the conference ... their presentation at ELCC): Making EGFR ... radiation in patients with locally advanced lung cancer: first ... lung cancer in organ transplant recipients, Hyperfractionated radiotherapy for ...
... PITTSBURGH, April 15 Certain genetic variations may be ... periodontitis, according to two recently published papers by researchers ... and their collaborators. Alexandre R. Vieira, D.D. S., ... professor of oral biology, and his colleagues at the ...
Cached Biology News:Researchers prove the gene responsible for Duchenne muscular dystrophy can be repaired 22nd European Lung Cancer Conference 22nd European Lung Cancer Conference 3Pitt Dental School researchers find susceptibility for caries, gum disease in genes 2